晶泰控股(2228.HK)事件点评:AI制药平台“再下一城” 公司进入价值兑现期

国联民生证券
Jan 13

事件:2026 年1 月7 日,晶泰科技宣布孵化企业ReviR 溪砾科技的小分子药物RTX-117 获得国家药监局临床试验批准,计划于1Q2026 启动I 期临床。该管线为国内首款针对腓骨肌萎缩症(CMT)的1 类创新药,也是 ReviR 与晶泰科技合作借助 AI+机器人辅助研发的一系列罕见病药物管线中首个进入临床的项目。RTX-117 创新产品走向临床,晶泰控股AI 平台价值进一步验证。RTX-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10